Contact

info@syndevrx.com

1 Broadway # 14, Cambridge, MA 02142

Co-Founder and Chief Business Officer James Shanahan Discusses Metabo-Oncology and Breast Cancer

Read More

AACR 2020: SynDevRx Selected to Present the Results from its Phase 1 Study of SDX-7320 in Late-Stage Cancer Patients

SynDevRx recently completed a Phase 1 study in late-stage cancer patients with a variety of solid tumors. The initial results from the clinical study were selected by AACR for presentation by one of the Principle Investigators – Dr. Monica Mita, MD. Dr. Mita is a Professor of Medicine, Co-Director, Experimental Therapeutics Program at Cedars-Sinai Medical […]

Read More

SynDevRx Dec 2019 San Antonio Poster on Hyperglycemia Inhibition with PI3K

SynDevRx Poster Dec 2019 SABCS Hyperglycemia PI3K

Read More

Insulin–PI3K signalling: an evolutionarily insulated metabolic driver of cancer

…insulin signaling can be seen as enabling tumor development by providing a mechanism for PI3K activation and enhanced glucose uptake. This idea is supported by studies showing enhanced tumor development in humans and mice with hyperinsulinemia, and reduced tumor development in states of reduced insulin levels.

Read More

Metabo-Oncology: The Latest Frontier in Cancer Research

There is a new field of cancer research that is only just now starting to take shape but is promising to greatly increase our understanding of cancer and what can influence how it develops over time. This field is being called metabo-oncology.

Read More

SynDevRx launches Metabo-Oncology.com website

Metabo-Oncology press release 26Mar 2019 FINAL

Read More

SDX at AACR: Obesity confers immuno-suppressive tumor microenvironment – Poster Presentation

April 1, 8:00 AM to 12:00 PM 1226 / 4 – A novel polymer-conjugated methionine aminopeptidase 2 (MetAP2) inhibitor SDX-7320 inhibits the growth of EO771 mammary gland tumors and ameliorates the immunosuppressive tumor immune micro-environment (TIME)

Read More

Increasing cancer rates among young adults tied to obesity

Rates of six different cancers that are associated with obesity increased among adults ages 25-49 between 1995 and 2014, according to the research, which was published in the journal Lancet Public Health and based on information in the Cancer in North America database. These cancers include multiple myeloma, colorectal, endometrial, gallbladder, kidney and pancreatic.

Read More

Dr. Lewis Cantley, PhD on the role of insulin in PI3K resistance

Dr. Lewis Cantley discusses targeting the PI3K pathway in breast cancer and the importance of managing ambient insulin levels during therapy.

Read More

Preclinical activity of SDX-7320 in mouse models of obesity and obesity-driven cancer

Cancer patients who are obese face a greater risk of dying from cancer compared to non-obese patients (Calle, 2003). Excess visceral adiposity is believed to contribute to metastasis and progression of cancer via multiple mechanisms: increased secretion of the adipose tissue hormone leptin, decreased secretion of adiponectin, increased production of estrogen in adipose tissue, and elevated insulin (secondary to peripheral insulin resistance) as well as the local effects of inflammatory cytokines (Gucalp, 2016).

Read More